Sichuan University

This study is testing a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has progressed after initial therapy. The goal is to see if this new combination is safe and can help control the cancer better tha…

This early-stage study is testing the safety of a new two-part treatment for people with advanced head & neck cancer or a type of esophageal cancer that has returned or spread. The treatment involves injecting a modified virus directly into a tumor to block its blood supply, whil…

This study is testing a three-part treatment for people with a hard-to-treat form of lung cancer that has spread to the liver and has worsened despite previous standard therapies. It combines targeted radiation to the liver with immunotherapy drugs and chemotherapy. The goal is t…

This early study is testing a new mRNA-based injection called WGb-0302 for patients with blood cancers like multiple myeloma that have returned or stopped responding to standard treatments. The treatment uses technology similar to some COVID-19 vaccines to deliver instructions th…

This early-stage study is testing a new experimental drug called WGb-0301 for people with advanced B-cell cancers (like certain leukemias and lymphomas) that have come back or stopped responding to standard treatments. The drug uses mRNA technology—similar to that in some COVID-1…

This study is testing whether adding a new drug called ivonescimab to standard chemotherapy (SOX) before and after surgery works better than standard chemo alone for people with locally advanced stomach cancer. About 154 participants will be randomly assigned to receive either th…

This study is testing whether a new system for tracking patient-reported symptoms after esophageal cancer surgery works better than standard care. It will involve 240 patients in China who have had surgery to remove their cancer. The goal is to see if actively monitoring and mana…